Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choo, Myung-Soo | - |
dc.contributor.author | Song, Miho | - |
dc.contributor.author | Kim, Jang Hwan | - |
dc.contributor.author | Lee, Kyu-Sung | - |
dc.contributor.author | Kim, Joon Chul | - |
dc.contributor.author | Kim, Sae Woong | - |
dc.contributor.author | Yang, Sang-Kuk | - |
dc.contributor.author | Lee, Jeong Gu | - |
dc.contributor.author | Lee, Jeong Zoo | - |
dc.contributor.author | Kim, Dae Kyung | - |
dc.contributor.author | Park, Won Hee | - |
dc.contributor.author | Kim, Kyung Do | - |
dc.contributor.author | Na, Yong Gil | - |
dc.contributor.author | Kwon, Dong Deuk | - |
dc.contributor.author | Paick, Jae-Seung | - |
dc.date.accessioned | 2021-09-05T10:17:21Z | - |
dc.date.available | 2021-09-05T10:17:21Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-04 | - |
dc.identifier.issn | 0090-4295 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98938 | - |
dc.description.abstract | OBJECTIVE To show the noninferiority of silodosin 8-mg once-daily (QD) to 4-mg twice-daily (BID) in efficacy and safety in patients with lower urinary tract symptoms or benign prostatic hyperplasia in the Korean population. METHODS A prospective, multicenter, double-blind, randomized, comparative study was conducted. A total of 532 male patients aged >= 50 years with lower urinary tract symptoms or benign prostatic hyperplasia were included. All patients received silodosin QD or BID for 12 weeks. The primary end point was the change from baseline in total International Prostate Symptom Score (IPSS) at 12 weeks. Adverse drug reactions, vital signs, and laboratory tests were recorded. RESULTS A total of 424 patients were randomized to the silodosin QD or BID groups. These groups were not significantly different in baseline characteristics. The mean total IPSS change in QD group was not inferior to that in BID group (-6.70 and -6.94, respectively; 95% confidence interval, -0.88 to 1.36). The QD and BID groups did not significantly differ in the following: percentages of patients with >= 25% (63.41% and 67.82%, respectively; P = .349) or >= 4-point improvement in total IPSS (65.85% and 69.31%, respectively; P = .457), maximum urinary flow rate improvement >= 30% (47.32% and 40.59%, respectively; P = .172), changes in IPSS voiding subscore (-4.42 +/- 4.93 and -4.65 +/- 4.77; P = .641), IPSS storage subscore (-2.05 +/- 3.07 and -2.52 +/- 2.97; P = .117), quality of life (-1.19 +/- 1.49 and -1.40 +/- 1.42; P = .136), maximum urinary flow rate (3.55 +/- 5.93 and 3.74 +/- 6.79 mL/s; P = .768), International Continence Society male questionnaire score, Patient Goal Achievement Score, or Treatment Satisfaction Question. The 2 groups had similar frequencies of adverse drug reactions. CONCLUSION QD administration of silodosin was not inferior to BID in efficacy. The 2 groups had similar adverse drug reaction profiles. (C) 2014 Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | ALPHA(1A)-ADRENOCEPTOR-SELECTIVE ANTAGONIST | - |
dc.subject | KMD-3213 | - |
dc.subject | SELECTIVITY | - |
dc.title | Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Jeong Gu | - |
dc.identifier.doi | 10.1016/j.urology.2013.11.013 | - |
dc.identifier.scopusid | 2-s2.0-84897381706 | - |
dc.identifier.wosid | 000333984000052 | - |
dc.identifier.bibliographicCitation | UROLOGY, v.83, no.4, pp.875 - 881 | - |
dc.relation.isPartOf | UROLOGY | - |
dc.citation.title | UROLOGY | - |
dc.citation.volume | 83 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 875 | - |
dc.citation.endPage | 881 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | ALPHA(1A)-ADRENOCEPTOR-SELECTIVE ANTAGONIST | - |
dc.subject.keywordPlus | KMD-3213 | - |
dc.subject.keywordPlus | SELECTIVITY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.